Monoclonal antibodies in renal transplantation: Preliminary results  by Russell, Paul S.
Kidney International, Vol. 20 (/98 1), pp. 530—537
NEPHROLOGY_FORUM
Monoclonal antibodies in renal transplantation:
Preliminary results
Principal discussant: PAUL S. RUSSELL
Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
Case presentation
A 51-yearo1d man was referred to the Massachusetts General
Hospital for evaluation of persistent proteinuria and azotemia. Five
years ago he underwent an emergency right femoral artery embolecto-
my for symptomatic impairment ofthe circulation in his legs. Abnormal
renal function first was discovered at that time. After an uneventful
postoperative course, the patient was admitted to the Hospital of the
University of Pennsylvania for further investigation. Mild hypertension
and bilateral cataracts were noted. Laboratory findings disclosed a
urine protein excretion of 2.2 g/day, a BUN of 40 nig/dI, and a serum
creatinine concentration of 2.8 mg/dl. The serum cholesterol and
triglyceride concentrations were 235 mg/dl. The serum calcium, phos-
phorus, and uric acid levels during allopurinol therapy for an episode of
podagra were normal. An intravenous pyelogram revealed scarred
kidneys, and retrograde pyelography suggested the possibility of papil-
lary necrosis. Rena! arteriography, normal except for moderate attenua-
lion of the smallest cortical arterial branches bilaterally, suggested
moderate nephrosclerosis. Aortoiliac atherosclerotic disease was pres-
ent.
The patient had no history of diabetes niellitus, sickle cell disease,
collagen vascular disease, or analgesic abuse. In addition, there was no
family history of renal disease.
The exact nature of his progressive renal failure remained unclear,
and attempts to manage it by diet and pharmacologic control of the
blood pressure were not wholly successful. The next 3 years witnessed
progressive elevations of the serum creatinine and BUN to 6.4 mg/dI
and 71 mg/dl, respectively. The patient complied poorly with various
programs of antihypertensive medication. Two years ago, results of
urinalysis revealed 4+ proteinuria and occasional hyaline and granular
casts with 0 to rare red and white blood cells. The urinary protein
excretion was 8.9 g/day, and the creatinine clearance was 24 L/day.
Further studies included a negative LE prep, a negative ANA, and a
negative test for Bence-Jones protein in the urine. An inferior vena
cavagram and bilateral renal venograms showed no evidence of renal
vein thrombosis. Renal ultrasonography demonstrated small kidneys,
which were 8 cm in length. This finding, coupled with a prolonged
bleeding time, precluded renal biopsy. The patient's medications in-
cluded clonidine , chlorothiazide, clofibrate, allopurinol, and potassium
chloride.
One year ago, a left radial artery-cephalic vein fistula was construct-
ed in anticipation of hemodialysis. Thrice-weekly hemodialysis was
instituted 10 months ago because of progressive symptoms of uremia
including incipient encephalopathy.
Five months after hemodialysis was begun, the patient received a
cadaver renal allograft in the right iliac fossa. None of the detectable
HLA specificities of the donor matched those of the patient. Immuno-
suppressive therapy consisted of azathioprine and prednisone. On the
12th postoperative day, the patient developed left-sided sciatica and a
temperature of 99° F. The serum creatinine climbed from a nadir of I .9
mg/dl to its zenith of 2.4 mg/dl over the next 3 days. A needle biopsy of
the allograft performed on the 16th postoperative day demonstrated a
dense interstitial infiltrate composed of lymphocytes and plasma cells
that was consistent with an acute cellular allograft rejection. A 10-day
course of treatment with a monoclonal antibody directed against all
peripheral blood T cells (OKT-3), given intravenously at 2 mg/day, was
started that day; the patient continued taking azathioprine and predni-
sone without changes in dosage. The patient developed a temperature
of 101.6° F and shaking chills about one hour after receiving the initial
dose of OKT-3 antibody; no other signs of toxicity were apparent and
subsequent antibody injections were well tolerated. The BUN and
serum creatinine levels peaked at 55 mg/dl and 4.8 mg/dl, respectively,
on the third day of OKT-3 immunotherapy and fell to 32 mg/dl and 2.1
mg/dl, respectively, on the 10th and final day oftherapy. Another renal
biopsy performed 2 days later showed a reduced cellular infiltrate.
Therapy with azathioprine and prednisone was continued (see Fig. 1).
Three months following transplantation. the patient continued to
receive azathioprine and prednisone, the dose of both being gradually
reduced; neither symptoms nor signs of further allograft dysfunction
were apparent. The serum creatinine concentration declined slowly to
1.6 ing/dI.
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opportunity to discuss a new approach to immunosuppression,
the utilization of monoclonal antibodies. Before discussing his
case in detail, I will explore some general aspects of transplant
rejection and its control. There is no doubt that the control of
allograft rejection continues to be the central problem in the
management of transplant recipients. Clinicians all agree that
the management of rejection and its attendant complications
strongly affects the survival of transplant recipients as well a.s
the expense of transplantation. In reviewing the expenses
involved in caring for kidney transplant recipients during the
first 3 months after operation, I was not surprised to learn that
caring for patients who lost their kidney transplants through
rejection was much more expensive than was caring for those
who did not (Fig. 2). Accordingly, several new approaches to
the management of transplant rejection are particularly wel-
come. These advances include:
(1) the management of blood transfusions;
(2) the elimination of passenger leukocytes" from the trans-
plant;
(3) more precise "cross-match" tests to evaluate the import
of humoral antibodies in intended recipients;
(4) thoracic duct drainage;
(5) cyclosporin A;
(6) total lymphatic irradiation;
(7) antibodies to lymphoid cells.
These approaches, each of which can influence significantly
transplant rejection, deserve careful and thorough consider-
ation. Although promising, the efficacy and drawbacks of each
are far from clear, and the relative merits of one approach
versus another are, in most cases, almost completely unknown.
This relatively new situation in transplant immunology, in
which several new approaches are available simultaneously,
offers a complex challenge to those in the field. How one should
approach these therapeutic choices in designing clinical trials,
especially when the numbers of patients available in individual
institutions are usually rather small, presents some demanding
problems. Much of the information forthcoming from small
clinical trials may be unreliable because of imperfections in
study design.
Although I plan to focus specifically on only one of these
advances, the utilization of monoclonal antibodies to lymphoid
cells, it might be instructive if I briefly comment on some of the
other new maneuvers currently under investigation.
Blood transfusion. Increasing evidence indicates that patients
who have received blood transfusions have a greater likelihood
of retaining their transplanted kidneys than do patients who
have never been transfused Ii]. Although the mechanism at
work here is far from clear, animal experiments suggest that
some kind of "instructive transaction" might be occurring, that
is, that the immune response of an individual who receives
blood is actually changed by exposure to that blood [2, 31. Some
researchers believe that the altered immune response of trans-
fused patients is more a matter of selection and that we
arbitrarily create two groups of individuals—one comprising
strong responders to immune stimuli and the other comprising
weak responders. These workers argue that the main effect of
transfusions is to ensure that only the weak responders receive
transplants [4]. 1 think the evidence militates against that being
the only mechanism, and that it is possible that several different
mechanisms are involved.
We know that leukocytes present in transfused blood share
cell-surface antigens with cells of the kidney. We also know that
repeated exposure to blood transfusions from a variety of
different donors can immunize an individual against antigens
that might be present in the transplanted kidney. In the past,
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Fig. 2. Totalhealth care costs for a group of29 patients during the first
3 months after transplantation. As illustrated, the cost per patient was
much higher when the transplant was lost.
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Fig. 1. Clinical course of the patient. Transplant function improved
dramatically in association with the 10-day course of treatment with a
monoclonal antibody to T lymphocytes (OKT-3).
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therefore, we refrained from transfusing patients with ordinary
whole blood. Instead, we selected blood prepared by freezing
and thawing, and we have been satisfied that such blood
transfusions were much less immunogenic to the patient be-
cause serial blood antibody determinations yielded evidence of
low rates of immunization.
Cyclosporin A. The agent cyclosporin A is of considerable
current interest and is under clinical trial by many transplant
units. There is no question that this drug is a potent immuno-
suppressive agent and that it probably can reduce the amount of
steroid required. Many problems still exist with the drug: it is
insoluble in water and has to be given in an oily suspension or
with a special solvent; it can be given by injection but it
frequently is more convenient to give it by mouth. Cyclosporin
A has been shown to cause transient, dose-related renal toxicity
in humans [5]. The research on cyclosporin A is still in its early
stages, and I am not aware of increased survival rates of
transplants in patients in whom this agent has been used with
lower doses of steroids or with none at all.
Total lymphatic irradiation. This approach, which uses man-
tle radiation (an inverted Y field), seems to render a patient less
immunologically reactive for quite a long time. This method
appears fairly successful in allowing organ transplantation in
certain primates [6], and efforts are currently underway to
explore this approach in patients.
I would like to turn now to a detailed examination of another
of these interesting new approaches to the management of
rejection, the use of antibodies in the control of transplant
rejection. Although my colleagues and I are actively interested
in several of the other possibilities, I believe that the use of
antibodies holds more promise than does any other technique
currently available. In presenting the account of a single patient
in a study now in progress by our group—Drs. Cosimi, Colvin,
and Burton, along with the close collaboration of Drs. Gold-
stein, Kung, and Rhodes of the Ortho Pharmaceutical Compa-
ny—I could be considered guilty of the very error that I
mentioned previously, that of overinterpretation of limited
information. Nevertheless, this single patient does provide a
clear example of the usefulness of monoclonal antibody thera-
py. Let us keep in mind, however, the hazards of extrapolating
results from such limited data.
Before I return to a discussion of the treatment in this patient,
let me provide some background in an effort to explain why we
inject an antibody produced by mouse cells into a patient to
control transplant rejection. The first recorded observations of
leukocyte destruction by antisera from a different species can
be traced to work by Metchnikoff in 1899 [7]. A number of
observations were recorded in the intervening years regarding
biologic effects of such xenospecific antibodies against leuko-
cytes, but in 1963 Woodruff and Anderson were the first to
show that the serum of rabbits immunized to rat thoracic duct
cells could have some potentiating effect on the immunosup-
pression obtained in rats subjected to thoracic duct drainage [81.
It was believed at that time that continuing treatment with sera
of this sort was associated with a waning immunosuppressive
effect that perhaps was largely due to the appearance of
antibodies in the recipients of the serum to the foreign protein
involved. At this stage some of my colleagues and I, along with
a number of investigators in other institutions, first became
involved in the field. A great deal of information emerged in the
subsequent few years, including the finding, for example, that
sera made in rabbits against mouse lymphoid cells could be
administered continuously without toxicity over a prolonged
period if contaminating antibodies to red cells and platelets
were removed by absorption [91. Such sera usually were
strongly immunosuppressive and allowed the survival of alloge-
neic skin grafts for many weeks, and the retention of skin
xenografts for at least one month as treatment was continued.
Fractionation of active sera proved that their immunosuppres-
sive capacity resided almost entirely in the IgG fraction [7]. No
clear principle regarding the selection of an optimal species for
immunization to produce immunosuppressive antibodies was
identified. Certainly it did not prove to be preferable to select a
species more distant from the cell donor. For example, the
guinea pig proved a much better source of antibody to mouse
cells for immunosuppression than did the dog [71. My col-
leagues and I also found that the ordinary histocompatibility
antigens by which members of a species differ were not
important in generating immunosuppressive sera; a serum made
against one strain of mouse cells was just as immunosuppres-
sive in members of a different strain as in the strain from which
the cells came [7].
These antilymphocyte sera also were effective in producing
greatly prolonged survival of kidney transplants in various
species. In experiments with canine kidney transplants, we
found that horse antidog serum extended the survival of canine
kidney transplants impressively, and in some cases led to
permanent survival [10]. The mechanism for the immunosup-
pression has been extensively debated, and it might be that
several mechanisms actually are involved. The main effect,
however, seems to be closely related to the deletion of T cells
from the peripheral blood and from lymphoid centers of treated
recipients.
We next initiated human trials in which the IgG fraction of
antisera made in horses against human thymocytes was em-
ployed [11]. A careful preliminary study was performed to
determine the optimal schedule for immunization of horses and
the IgG fraction of the sera of immunized horses was prepared.
The first trials employed sera that we made ourselves, whereas
subsequent trials made use of sera prepared, using much the
same methods, by the Upjohn Company. One problem all along
has been the considerable variation in immunosuppressive
capacity that can occur from one batch of serum to another.
Some batches suppressed the peripheral blood T cells of
patients more than other batches did, as determined by serial
counts of T cells by the sheep red blood cell rosetting tech-
nique. It was found that horse antihuman thymocyte IgG could
be administered intravenously into a central vein or an arterio-
venous fistula with relatively few side effects. Although fever,
occasional skin rashes, and thrombocytopenia occurred, we
were forced to discontinue serum treatment only rarely.
The clinical trials were of two types. In the first, patients
receiving kidney transplants from unrelated donors were ran-
domly assigned either to antithymocyte globulin (ATG) treat-
ment for 4 weeks plus standard immunosuppressive treatment
beginning at the time of transplantation, or to standard immuno-
suppressive therapy alone [II]. We used ATG in dosages
ranging from 500 to 1000 mg per day with frequent adjustment
of dosage to keep rosetting cell numbers at about 5% to 10% of
pretreatment levels in the peripheral blood. This first study,
Monodonal antibodies 533
part of a larger interinstitutional one, yielded several valuabIe
conclusions: (1) allograft survival was improved by about 20%
in our group of patients when we used active preparations; (2)
no fully reliable means of assessing the immunosuppressive
potency of a given batch of material was found, although the
effect of treatment on circulating T cell numbers was the most
useful guide; (3) the total amount of steroid treatment required
to control rejection was less; and (4) the time of onset of first
rejection reactions was delayed. Accordingly, we found our-
selves persuaded of the immunosuppressive capacity of ATG in
kidney transplant recipients.
In the other study, we utilized patients receiving kidney
transplants from living related donors who were haploidenti-
cal. These patients received standard immunosuppressive ther-
apy and only were treated with ATG for 2 weeks when acute
rejection interfered with renal function [12]. The diagnosis of
acute rejection was made according to carefully defined crite-
ria, and the patients were divided into an ATG-treated group
and a group treated with increased steroid dosage. Rejection
was promptly reversed in all 10 patients in the ATG group,
although one patient experienced repeated rejection reactions
and eventually lost the kidney. Nine of 10 of these allografis
continue to function; 8 patients are maintaining serum creati-
nine levels of less than 2.0 mg/dl. One patient has a creatinine
level of 3.5 mg/dl in association with a poorly functioning
bladder of congenital origin. One of 10 patients in the steroid-
treated group died of infectious complications; renal function in
3 of the 9 survivors is impaired. The total steroid dose in the
ATG-treated patients was approximately that received by pa-
tients who never experienced rejection, that is, a mean cumula-
tive dose of 52 mg/kg in the first 60 days after transplantatiort.
Patients receiving additional steroids for rejection received
much more, a mean cumulative dose of 121 mg/kg at 60 days.
Nevertheless, the use of ATG involved certain drawbacks.
including the variability of the material from one batch to the
next and the necessity of giving fairly large amounts of foreign
protein, only a small proportion of which consisted of active
molecules. Although the rosetting test was useful, its utility was
confined to patients receiving ATG, as no consistent changes
were observed in patients treated with conventional immunc-
suppressive agents.
As we were conducting these studies, the striking new
technology of monoclonal antibody production by suitable
hybridized cells was described by Kohler and Milstein [131.
This technology has been greatly potentiated by the simulta-
neous development of a new family of instruments, the flow cy-
torneters. Flow cytometry has developed rapidly from the
contributions of a number of individuals, but its use in conjunc-
tion with antibodies specific for distinguishing cell-surface
markers depended on the work of Herzenberg and colleagues at
Stanford [141. Their instruments were designed to permit the
sorting of cells bearing characteristic markers. Each cell was
separated into a discrete droplet of fluid and then deflected into
separate containers depending on whether the cells had reacted
with and were thus coated with a test fluoresceinated antibody.
Another family of instruments has concentrated on the enumer-
ation of antibody-tagged cells and on the analysis of many
different cell suspensions in rapid succession. Buffy-coat cell
preparations instead of purified lymphocyte suspensions can
now be used. Our modified, prototype instrument (from the
Table 1. Normal human lymphocytes
Cell detected Mean % positive No. of patients
std. error tested
All T cells
Helper/inducer T cells
Suppressor/cytotoxic
T cells
Thymocyte
Ortho Diagnostic Systems Company) is fitted with a small
computer that makes the analysis and recording of large
amounts of data relatively easy.
We are currently testing a group of monoclonal antibodies
made from hybridized mouse cells. Most of these hybridomas
against human T cells were made by Drs. P. Kung arid 0.
Goldstein at the Ortho Pharmaceutical Company and are desig-
nated as the OKT series of monoclonal agents. The process
consists of immunizing mice with suspensions of human T cells.
Then, antibody-producing cells are separated from the mouse
spleens and are fused with cells from a mouse myeloma in vitro.
Such hybrid cells can divide indefinitely in tissue culture or as
ascites tumors in the peritoneal cavities of mice while still
producing the specific antibody made by the antibody-produc-
ing parent cell. Thus, an immortal line of cells emerges that is
capable of producing a monoclonal antibody. The main chal-
lenge is selecting from a myriad of different hybridomas those
capable of producing antibody against a particular set of cell-
surface components. Our colleagues at the Ortho Pharmaceuti-
cal Company have accomplished this task, and a series of tests
of the in vitro characteristics of certain of these antibodies have
been carried out by Reinherz and colleagues [15].
Using several of these antibodies against cell-surface compo-
nents, we found that peripheral blood lymphocytes of normal
individuals, or of patients on hemodialysis, can be differentially
counted as displayed in Table I. The percentage of peripheral
blood cells identified as T cells by the E-rosetting technique
(70.1 3.4%) was approximately the same as the percentage
reactive with one of the monoclonal antibodies (OKT-3) (72.8
1.4%). The latter determination now can be performed on less
purified cell preparations in a much more convenient fashion;
therefore, it has largely superceded E-rosetting in our labora-
tory. Also, quantitative information about subsets of T cells
appears to be quite helpful in our understanding of immunologic
events occurring in patients taking immunosuppressive thera-
py, either monoclonal antibody to lymphocytes or conventional
agents. Figure 3 depicts the alterations in two important subsets
of T cells observed in association with certain clinical events
after renal transplantation in one patient. This patient received
an allograft from an unrelated donor and was treated in the
standard fashion with azathioprine and prednisone. After a
period of satisfactory allograft function, lymphocyte monitoring
revealed that OKT-4—reactive cells (the helper/inducer subset)
accounted for approximately 60% of peripheral lymphocytes,
whereas OKT-8—positive cells (the suppressor/cytotoxic sub-
set) accounted for fewer than 20%. The ratio thus was about
normal, that is, about 2 : I or higher. Renal function then
deteriorated in the presence of this cell pattern, and a biopsy of
the allograft confirmed the presence of acute cellular rejection.
Monoclonal
antibody
OKT-3
OKT-4
OKT-8
OKT-6
4/8 ratio
72.8 1.4
46.1 1.2
25.1 1.2
0.7 0.2
2.00 0.14
32
33
33
29
33
Rejection episode
Yes—12 episodes
No—IS episodes
4/8 ratio
(mean ratio for each group)
a)
J1
Days posttransplant
Fig. 3. Clinical course and changes that occurred in two important
subsets of the peripheral blood T-cell population of a recipient of a
kidney transplant during the first 3 months pt'ier operation. PBL refers
to peripheral blood lymphocytes,
High doses of prednisone subsequently reversed the rejection
crisis. A period of stable renal function followed during which it
was noted that the relative proportions of the OKT-4— and
OKT-8—reactive cells gradually reversed. At this time, renal
allograft function again deteriorated, but clinical evaluation
strongly suggested a viral cause. Allograft biopsy revealed a
glomerulopathy that we believe is associated with cytomegalo-
virus infection (CMV), and buffy-coat cultures later were
proved to be positive for CMV. Because of these findings,
immunosuppressive therapy was reduced despite allograft dys-
function. As the viral syndrome resolved, the patient's serum
creatinine fell to approximately 2.5 mg/dl, and continuing T-cell
subset monitoring showed approximately equal proportions of
OKT-4— and OKT-8—positive cells during this period. Several
other patients whom we have studied also have developed
clinical syndromes due to herpes viruses at a time when their
cell ratios were similar to that observed in this patient during his
second period of declining renal function. We thus have gained
the impression that a high ratio of OKT-8—positive cells to
OKT-4—positive cells is a situation in which the viral infection is
more likely to be the cause of declining renal function.
Our early results with monitoring T-cell subsets in 144
allograft recipients are reported in detail elsewhere [16—18], In
summary, we found that patients who maintain a greater
number of OKT-4— than OKT-8—reactive cells in their peripher-
al blood, as do normal subjects, appear to be at a relatively high
risk of developing acute rejection reactions. In contrast, a
relatively small percentage of patients whose peripheral blood
contained an excess of OKT-8— over OKT-4—reactive cells
underwent acute rejection. These findings are summarized in
Table 2. Many new monoclonal antibodies will be discovered,
of course, and our ability to interpret findings with those
presently available will progress rapidly. We have already
found, for example, that OKT-10—positive cells, which usually
are confined almost entirely to the thymus, may flood into the
peripheral blood in considerable numbers in immunosuppressed
patients. It will be of interest to determine the significance of
this event.
At last we return to the patient under consideration today. He
illustrates the ability of a monoclonal antibody of murine origin
to reverse an acute rejection reaction in a kidney transplant
recipient. The antibody selected for these early trials is one that
reacts with all peripheral blood T cells (OKT-3). It is an lgG2b
antibody that fixes complement and can block cytotoxic T cells
in vitro [19]. The patient had reached end-stage renal failure of
uncertain cause, but he was otherwise relatively healthy except
for evidence of widespread atherosclerotic disease. He under-
went kidney transplantation from an unrelated donor without
special incident except that the donor kidney had probably
undergone moderate ischemic damage prior to transplantation.
Although the transplanted kidney functioned promptly, the
glomerular filtration rate only gradually increased to normal, so
that after transplantation the patient's serum creatinine fell
slowly. By the 15th day after operation, the serum creatinine
had reached a low of 1.9 mg/dl, and a typical early acute
rejection reaction began. A needle biopsy of the transplanted
kidney was performed on the 16th day as the rejection reaction
was progressing. The decision was made to offer the patient an
opportunity to participate in the new study of the use of a
monoclonal anti—T-cell reagent in early acute rejection. After
securing his consent, we gave the patient an intravenous
injection of 2 mg of OKT-3. Serial blood samples were taken,
and we observed that as early as 5 minutes after he received the
antibody, all recognizable T cells in the peripheral blood had
disappeared (Fig. 4). Appropriate controls were performed to
assure that OKT-3—reactive cells were indeed cleared from the
circulation rather than simply being coated with antibody.
Within 45 minutes he had a mild chill and a transient fever of
101.6° F. The patient was given daily infusions of 2 mg of
antibody for 10 days; he completed the course of treatment with
no further side effects and his rejection reaction responded
decisively to this new form of therapy. Daily urine volume rose
from a pretreatment level of 1600 ml to almost 3000 ml by the
fourth day of therapy. Serum creatinine began to decline by the
fourth day of treatment and fell thereafter to 1.2 mg/dl by the
30th day (see Fig. 4). The dose of prednisone was reduced
steadily according to our standard protocol as though no
rejection had taken place. In the succeeding 3-month period,
the patient has had evidence of mild rejection, and his serum
creatinine is currently 1 .6 mgldl.
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Table 2. Impact of peripheral blood OKT-4/OKT-8 ratios on the
likelihood of renal transplant rejection
4>8 8>4
10
2
2.6 0.3
2
13
0.4 0.6
p = 0.0004
Fisher's exact test evaluating association of T-cell changes with
rejection.
Normal
OKT4
(48 7)
Normal
OKT-8
(25 7)
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Fig. 4. A. Fluorescence histogram of this patient's peripheral blood
lymphocytes reactive with OKT-3 antibody prior to treatment. The
pattern shown is within the normal range. B. Five minutes after an
intravenous injection of 2 mg of OKT-3 antibody, over 90% of cells
reactive with this antibody disappeared from the circulation.
Of course it is far too soon for us to draw any conclusions
about the optimal use of monoclonal antibodies in immunoregu-
latory treatment. The main purpose of this presentation is to
call attention to the existence of these powerful new methods
for evaluating the immune status of patients and their potential
for regulating numbers of immunocompetent cells of a given
type in the peripheral blood. Clearly these new opportunities
have many applications outside of transplantation immunology
and some of these are being explored at present.
Questions and answers
DR. JOHN T. HARRINGTON: Dr. Russell, I'd like to thank you
for sharing this exciting new development with us. Do you have
information about the results of the administration of monoclo
nal antibodies at other transplant centers?
DR. RUSSELL: There is no other experience with the use of
monoclonal antibodies for immunosuppression in patients as far
as I know. These agents also can be used in bone marrow
transplantation. Efforts have been made to treat the bone
marrow in transit between the donor and the recipient to try to
eliminate immunologically active cells in vitro before the inno-
culum of cells is transferred into the recipient. There have been
some encouraging results with this approach in London and, I
think, in Boston at the Children's Hospital. I don't know
exactly where that stands. But I don't think there is any more
information to date than what I have given you about its use in
kidney transplantation.
DR. JEROME P. KASSIRER: As we become more efficient in
suppressing or eliminating lymphocytes, we become increasing-
ly effective in preventing rejection. But what are the adverse
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A consequences of eliminating various kinds of lymphocytes in
such a nonspecific fashion?
DR. RUSSELL: That's a very important and significant ques-
tion. We must be extremely aware of the danger of infection,
especially viral infections. It is too early to say how often viral
infections will occur in association with the use of monoclonal
antibodies against all T cells. The third patient in our short
series has developed severe herpes labialis and I think we have
to anticipate that such infections may pose a real problem; it's
already become something of a problem with the use of the
other, more standard ATG reagents. One also might ask wheth-
er the incidence of neoplasia will increase with this kind of
immunosuppression. People vary in their guesses as to why
immunosuppressed patients get cancer significantly more fre-
quently than do untreated individuals. My own hunch is that
this phenomenon might be related to the intrusion of certain
viruses into the patient in the presence of immunosuppression.
It is unsatisfactory, of course, to base treatment on the elirnina-
tion of all T cells, and I will be gratified when we can begin to
adjust the numbers of subsets of T cells individually. Take, for
example, the possibility of treating only to adjust the levels of
OKT-4 cells, the helper cells, which promote immune respons-
es. If we could regulate them and control immune responses
without deleting other cells, it might be less dangerous. This is
one of a number of important possibilities that now await
exploration.
DR. JORDAN J. COHEN: It is quite common, when we follow
renal transplant patients, to witness one, two, or even more
rejection episodes within the first few months but none thereaf-
ter despite the same, or even a lower, dose of immunosuppres-
sive agents. It is as if the graft has to settle in" for a while
before being accepted. Do you think that monitoring the pattern
of T cells with specific monoclonal antibodies will clarify this
puzzling phenomenon?
DR. RUSSELL: I agree with you completely that that is the
case. Certainly many patients require less immunosuppression
and have many fewer rejection episodes with the passage of
time. I am convinced from that, as I guess you are, that an
"accommodation" takes place between the graft and the host.
We now have increasing evidence from animal experiments that
the kidney can induce this kind of a change under certain
immunogenetic circumstances, and we are trying to promote
this kind of accommodation. If we can suppress the activity of
helper cells during a limited period, we might find a way of
accomplishing this. We are particularly interested in doing this
kind of experiment, which we may be able to accomplish in
primates.
DR. COHEN: Even before considering what intervention
might be useful in promoting graft survival, it would be interest-
ing to see whether the changing pattern of T-cell subsets
correlates with eventual graft "acceptance."
DR. RUSSELL: We are certainly going to look very carefully
for that. So far the principal changes we have noted have lo do
with the ratio of OKT-4— to OKT-8—positive cells, which I have
mentioned. We haven't followed patients long enough yet to
say much about long-term changes.
DR. HARRINGTON: Clinical investigators have sought for a
rapid, simple, and accurate way of diagnosing rejection for
many years, preferably within the first 24 hours or so. You
showed that a high ratio of OKT-4!OKT-8 correlates well with
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rejection. Have you examined this finding prospectively to test
whether one can predict 24 to 48 hours ahead whether rejection
is going to occur?
DR. RUSSELL: We had hoped that we might have such a test,
and, as you indicate, it would be of great advantage if one could
be found. So far the suggestion is that a high OKT-4/OKT-8
ratio sets the stage for rejection. Conversely, it is unlikely that
rejection will occur if the patient has a high OKT-8/OKT-4
ratio. I gave you one example in which we actually acted upon
that information. Whether this ratio will prove reliable enough
to suggest early action on a regular basis is unclear. So far,
however, the statistical significance of these ratios appears very
strong.
DR. KASSIRER: Raising an antibody to helper cells or suppres-
sor cells is not a very specific approach to immunosuppression
in a patient with a transplant. Do these hybridoma techniques
raise the promise that in the near future we will be able to
develop immunosuppressive materials targeted against antibod-
ies to specific transplantation antigens in the implanted organ?
DR. RUSSELL: Monoclonal antibodies can be as specific as
antibodies can be, so that one could produce antiidiotypic
antibodies with hybridomas, for example. That is an interesting
avenue for exploration, as this might be one approach to
specific immune alteration of recipients. I understand the
import of your question, which is very telling. We do need to
approach immunosuppression in such a way as to yield a
specific alteration in immune responsiveness. My present feel-
ing is that one reasonable approach to this is to alter the immune
system of the recipient initially and then imprint on that altered
recipient the donor antigens in some form, At present I believe
we are doing this to a degree with the transplant itself. One
might consider doing it with pretranspiant exposure of the
potential recipient to lymphoid cells, platelets, or some other
antigen preparation of donor origin; the depression of helper
cells to set the stage for this may prove a useful adjunct.
DR. MICHAEL MADAIO (Renal Service, NEMC): Do these
patients develop antimouse antibodies? In other words, is the
use of monoclonal antibodies a one-time therapy, or if acute
rejection develops in the future, can these patients he treated
again with the same sort of therapy?
DR. RUSSELL: This could be an important question for us. In
the early days, when horse ALG was given intramuscularly and
at lower dosage, some patients developed high titers to horse
protein. Now that we give it intravenously and in higher doses,
we almost never see antibodies to horse protein. We haven't
found any antibodies so far in the 3 patients I mentioned who
received the mouse protein, and I would probably treat them
again after discontinuing treatment for a period; but it's a
concern for ju'st the reason you mentioned.
DR. JAMES STROM (Renal Division, St. Elizabeth's Hospital,
Boston, Mass.): As I understand it, the first step in preparing
monoclonal antibodies to T cells is to immunize an animal
against whole thymus. I am puzzled about how you separate out
all the resulting antibodies so that you get, for example, all the
anti—OKT-3s in one pool.
DR. RUSSELL: It has to be done on an individual cell basis.
Thus, one prepares a hybrid of an antibody-producing cell with
a rnyeloma cell and each individual hybridized cell is delivered
into a separate culture well. Thereafter it may or may not grow
into a clone. Each clone is composed of identical hybrid cells
from one progenitor antibody-producing cell. One next tests the
supernatant fluid in each well to see what antibody is being
produced by that particular clone. Antibodies to T cells are
tested by determining what types of T cells they react with in
vitro where the functional characteristics of T-cell subsets can
be determined. So it involves sorting through hundreds of
antibody-producing hybridomas until you find the right ones.
DR. ANDREW LEVEY (Renal Service, NEMC): First, by using
monoclonal antibodies as reagents to monitor a recipient's
response, can you tell what happens to T-cell subsets in the first
4 or 5 days after renal transplantation when treatment is limited
to azathiaprine and prednisone? Second, can one determine
what fraction of the recipient's lymphocytes is actually "turned
on" by the event?
DR. RUSSELL: There tends to be a general lymphopenia with
steroid treatment, but the relative numbers of, for example,
OKT-4 and OKT-8 cells may remain the same. We have
concentrated on changes in the relative numbers of the various
T cells over time and the consequences of the changes are what
I have tried to describe. I am afraid I cannot say what fraction
of the lymphoid cell population in the patient is activated to the
antigens in the transplant by examining the peripheral blood.
Please bear in mind also that the antigens that distinguish the
different subclasses of T cells by their functional capacities are
not the same antigens as those by which the cells of an
individual can be distinguished from another individual.
DR. LEVEY: Have there been any attempts to prevent recog-
nition of the donor kidney by the host lymphocytes either by
disguising the antigens in the donor kidney or by inhibiting or
removing specific lymphocytes that recognize those antigens?
DR. RUSSELL: The disguising of antigens in a donor tissue by
covering them with an appropriate antibody has not been very
successful. Another approach, similar in concept, would be the
elimination of the more antigenic cells in a transplant. If one
could do this without functionally altering the donor tissue, it
could be worthwhile. As I see it at present, that is the most
hopeful possibility, in the category of immunologic alterations
of the donor tissue, that is under investigation at present.
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